Evidence map›Paper›PMID 41567498›Full record

ArticleEndoscopy international open2026

Endoscopic ultrasound molecular evaluation of pancreatic cancer trial to profile molecular landscape of inoperable pancreatic ductal adenocarcinoma.

Owen McKay, Joanne Lundy, Sally Bell, Phil Ha, Hugh Gao, Brendan Jenkins, Chamkaushalya Bulathsinghalage, Michael Swan, Simon Hew, Belinda Lee and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endoscopy international open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Owen McKayGastroenterology and Hepatology, Monash Health, Melbourne, Australia.ORCID 0000-0001-8280-216X
Joanne LundyMedical Oncology, Peninsula Health, Frankston, Australia.
Sally BellGastroenterology and Hepatology, Monash Health, Melbourne, Australia.
Phil HaGastroenterology & Hepatology, Peninsula Health, Frankston, Australia.
Hugh GaoFaculty of Medicine, Nursing and Health Sciences, Department of Surgery, Monash University, Melbourne, Australia.
Brendan JenkinsSouth Australian ImmunoGENomics Cancer Institute (SAiGENCI), Adelaide University, Adelaide, Australia.
Chamkaushalya BulathsinghalageUpper Gastrointestinal Surgery, Monash Health, Clayton, Australia.
Michael SwanGastroenterology & Hepatology, Monash Health, Clayton, Australia.
Simon HewGastroenterology & Hepatology, Monash Health, Clayton, Australia.
Belinda LeeMedical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Pranav DorwalGenomics & Anatomical Pathology, Monash Health, Clayton, Australia.
Manoop S BhutaniGastroenterology, University of Texas MD Anderson Cancer Center, Houston, United States.
Vivek RathiGenomics & Anatomical Pathology and Lifestrands Genomics Australia, Monash Health, Clayton, Australia.
Sean GrimmondCollaborative Centre for Genomic Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia.
Andrew PerryMonash Genomics & Bioinformatics Platform, Monash University, Melbourne, Australia.
Trevor WilsonHudson Genomics Facility, Hudson Institute of Medical Research, Clayton, Australia.
Andrew StricklandMedical Oncology, Monash Health, Clayton, Australia.
John ZalcbergMedical Oncology, Alfred Health, Melbourne, Australia.
Daniel CroaghUpper Gastrointestinal Surgery, Monash Health, Clayton, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and study aims: Pancreatic ductal adenocarcinoma (PDAC) is a poor prognostic malignancy. Comprehensive genomic profiling (CGP) has improved outcomes in many cancers, but widespread uptake in PDAC remains elusive. This study investigated the feasibility of using endoscopic ultrasound with fine-needle biopsy (EUS-FNB) for CGP in advanced PDAC. Patients and methods experimental design: A multicenter prospective cohort study was conducted to assess the feasibility of using DNA and RNA extracted from fresh frozen or archival formalin-fixed paraffin-embedded (FFPE) EUS-FNB for CGP on advanced PDAC using the TSO-500 gene panel testing. Results of the CGP were reviewed at a molecular tumor board (MTB) and subsequent treatment recommendations were forwarded to the referring clinicians. Results: CGP was successful in 129 of 143 patients (90%) enrolled between May 2020 to September 2023. Fresh frozen EUS-FNB provided suitable genetic material for CGP in 123 of 133 patients (92%). Conversely, CGP was successful on FFPE biopsy blocks from only six of 16 patients (38%). Fifty-two of 143 patients (36%) had a potentially targetable mutation detected, and eight of these patients (6%) were treated with targeted therapy based on their EUS-FNB-derived molecular profile. Patients who received personalized therapy had a significant ( Conclusions: This real-world study confirms the feasibility and utility of CGP using EUS-FNB in advanced PDAC. It illustrates the importance of timely access to personalized therapy informed by CGP, which can impact the treatment pathway and improve survival outcomes.

Indexed as

Endoscopic ultrasonographyFine-needle aspiration/biopsyPancreasTissue diagnosis

Identifiers

PMID41567498
PMCPMC12817188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.